Beximco Pharmaceuticals PLC. (DSE:BXPHARMA)
Bangladesh flag Bangladesh · Delayed Price · Currency is BDT
153.20
+5.20 (3.51%)
At close: Sep 3, 2026

DSE:BXPHARMA Cash Flow Statement

Millions BDT. Fiscal year is Jul - Jun.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Net Income
8,6506,9415,8304,6145,1235,128
Depreciation & Amortization
1,8751,8001,9942,0611,6671,114
Other Amortization
32.6932.69----
Loss (Gain) From Sale of Assets
-43.37-34.93-16.38-13.82-12.62-3.96
Asset Writedown & Restructuring Costs
184.5184.5----
Other Operating Activities
217122.15124.15158.2346.0960.3
Change in Accounts Receivable
690.05172.26-181.71-442.8352.25431.61
Change in Inventory
-247.12-1,371-61.78-1,829-2,565-1,084
Change in Accounts Payable
-1,144-688.95149.41,060-9.72587.17
Change in Income Taxes
488.7638.03-92.37323.65-156.05-63.38
Change in Other Net Operating Assets
-235.3327.72619.81154.32469.16-146.06
Operating Cash Flow
10,4687,2238,3646,0855,2146,023
Operating Cash Flow Growth
74.86%-13.65%37.46%16.70%-13.43%8.67%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Capital Expenditures
-3,225-2,781-1,994-2,411-2,815-2,521
Sale of Property, Plant & Equipment
31.5660.3326.9623.3524.0632.83
Cash Acquisitions
-----4,767-
Sale (Purchase) of Intangibles
-348.1-247.94-240.83-231.54-124.29-37.73
Investment in Securities
-50-700-200---
Other Investing Activities
1.260.971.141.932.020.94
Investing Cash Flow
-3,591-3,668-2,406-2,617-7,680-2,525

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Short-Term Debt Issued
----1,508-
Long-Term Debt Issued
----2,731-
Total Debt Issued
-1,437---4,238-
Short-Term Debt Repaid
--971.27-3,625-229.38--2,375
Long-Term Debt Repaid
--152.52-1,049-1,763--504.64
Total Debt Repaid
-2,893-1,124-4,674-1,993--2,880
Net Debt Issued (Repaid)
-4,330-1,124-4,674-1,9934,238-2,880
Common Dividends Paid
-211.55-1,603-1,586-1,568-1,623-578.35
Financing Cash Flow
-4,542-2,727-6,260-3,5612,615-3,458

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Foreign Exchange Rate Adjustments
9.5218.2220.2959.8145.36-
Net Cash Flow
2,345845.99-281.58-32.99194.7140.45

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Free Cash Flow
7,2424,4416,3713,6742,3993,503
Free Cash Flow Growth
130.26%-30.29%73.40%53.15%-31.51%6.17%
Free Cash Flow Margin
13.43%9.04%14.35%9.36%6.92%11.88%
Free Cash Flow Per Share
16.239.9614.288.245.387.85
Levered Free Cash Flow
4,1722,3104,3111,909-1,0041,799
Unlevered Free Cash Flow
4,5982,9125,0112,685-425.732,303

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Cash Interest Paid
739.24976.731,1491,2721,002861.45
Cash Income Tax Paid
2,0241,9701,7301,1451,3471,450
Change in Working Capital
-447.16-1,822433.35-734.17-1,909-274.95